---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122830"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:37:33.788668+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aptevo Q3 net loss $5.1M; cash $7.8M; initiates RAINIER trial for AML

## Summary
- Net loss of $5.1M ($0.48 per share) in Q3 2024 vs $6.3M ($22.16) in Q3 2023.
- Cash and cash equivalents $7.8M as of Sept 30, 2024, down from $16.9M at Dec 31, 2023.
- Initiated Phase 1b/2 RAINIER trial for mipletamig in frontline AML based on positive dose escalation data.
- ALG.APV-527 Phase 1 data: 60% of evaluable patients (9/15) achieved stable disease as monotherapy.
- Raised $5.75M in two financings during the quarter.

## SEC filing metadata
- accession: 0000950170-24-122830
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017024122830/0000950170-24-122830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017024122830/apvo-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122830
- JSON: https://secwatch.observer/filing/0000950170-24-122830.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.